About Yifan Tu

Overview

When it comes to treating her cancer patients, Dr. Tu believes it's important to understand not just the disease, but the whole person—their lives, successes and struggles. Through this, she can better assess her patients' healthcare needs and provide treatments, comfort and strength during what is often a very difficult time. Board certified in internal medicine, medical oncology and hematology, Dr. Tu has particular interest in breast cancer and has conducted clinical research in that area. When she isn't caring for patients, she's living her faith by participating in Christian fellowship in St. Louis, serving students from China and introducing them to Jesus Christ. She also enjoys spending time with her husband and their son—and sneaking treats to the family dog, a Labrador retriever.

Services

Cancer

Specialties

Hematology Oncology, Hematology, Medical Oncology

Departments

Cancer

Credentials

Certifications

  • American Board of Internal Medicine: Hematology/Oncology
  • American Board of Internal Medicine: Internal Medicine
  • Educational Commission for Foreign Medical Graduates

Education

  • 2000, Medical Center of Fudan University, MD
  • 2008, University of Massachusetts, PhD

Residency

  • 2011, New York Medical College

Fellowship

  • 2014, Albert Einstein College of Medicine

Professional Affiliations

  • American Society of Clinical Oncology
  • American Society of Hematology
  • Chinese American Hematologist Oncologist Network

Office Locations

Southeast Cancer Center

789 South Mount Auburn Road
Cape Girardeau, MO 63703    Maps & Directions
Phone: 573-519-4830

Media

SoutheastHEALTH is pleased to welcome Dr. Yifan Tu as Hematologist/Oncologist at the Southeast Cancer Center. When it comes to her patients, providing exceptional treatment in a caring, compassionate environment is paramount.

Publications & Research

  • Tu Y, Huang Q, Zhao XF. Dopamine in form-deprived myopia. Chinese Journal of Optometry and Ophthalmology. 2002, 4(3): 190-192.
  • Zhang J, Tu Y, Schneider SS. Activation of p53, inhibition of telomerase activity, and induction of estrogen receptor beta are associated with the anti-growth effects of combination ovarian hormones and retinoids in immortalized human mammary epithelial cells. Cancer Cell International, 2005, 5(6).
  • Tu Y, Pazik B, Jerry DJ, Schneider SS. Sensitivity to DNA damage is a common component of hormone based strategies for protection of the mammary gland. Molecular Cancer Research, 2005 Aug, 3(8): 435-42.
  • Tu Y, Robert L, Schneider SS. Rhodiola crenulata induces death and inhibits growth of breast cancer cell lines. Journal of Medicinal Food. 2008 Sep;11(3):413-23
  • Tu Y, Hershman D, Pellegrino C, Andreopoulou E, Makower D, Kalinsky K, Fehn K, Finberg S, Bhalla K, Sparano J. A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer. Breast Cancer Res Treat. 2014 Jul;146(1):145-52
  • Kalinsky K, Lim E, Andreopoulou E, Desai A, Jin Z, Tu Y, Wang A, Hibshoosh H, Greenlee H, Crew K, Maurer M, Hershman D. Increased Expression of Tumor Proliferation Genes in Hispanic Women with Early-Stage Breast Cancer as Compared to Non-Hispanic White Women. Cancer Invest. 2014 Nov;32(9):439-44
  • Ahmed F, Fohne L, Muzaffa R, Kelly P, Fernandez H, Tu Y, et al. Bone metastasis as detected by FDG PET with negative CT of the PET/CT: Frequency in 20000 scans. Front Oncol. 2016 Oct 10;6:208. 
  • Ravulapati S, Leung C, Poddar N, Tu Y. Immunotherapy in Squamous Cell Skin Carcinoma -- A Game Changer? ? American Journal of Medicine. 2017 DOI: http://dx.doi.org/10.1016/j.amjmed.2016.12.020

Abstracts:

  • Tu Y, Pazik B, Jerry DJ, Schneider SS. Sensitivity to DNA damage is a common component of hormone based strategies for protection of the mammary gland. American Association of Cancer Research (AACR)2005 annual meeting. Abstract #5383 
  • Kalinsky K, Andreopoulou E, Tu Y, Sparano J, et al. Ethnic difference in tumor proliferation in women with early-stage breast cancer. American Society of Clinical Oncology (ASCO) 2013 annual meeting. Abstract # 560 
  • Tu Y, Hershman D, Pellegrino C, Andreopoulou E, Makower D, Kalinsky K, Fehn K, Finberg S, Bhalla K, Sparano J. A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer. American Society of Clinical Oncology (ASCO) 2014 annual meeting. Abstract # 598 
  • Gildstein D, Clark J, Tu Y, et al. Global Differences in Affordability of Cancer Drugs. American Society of Clinical Oncology (ASCO) 2016. Abstract #LBA 6500 http://www.ascopost.com/News/41632 
  • Mehta H, Farhat R, Ravulapati S, Tu Y. Relevance of Rapid Geriatric Assessment for Elderly Patients with Newly Diagnosed Malignancy. ASCO palliative care symposium 2017. Abstract #115
  • Seigel C, Gill A, Esteghramat N, Tu Y, Rodin M. Barriers to Online Patient Portal adoption among Adult Oncology patients. ASCO palliative care symposium 2017. Abstract #44